Stock AnalizAmylyx Pharmaceuticals, Inc. AMLX
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) is a healthcare company listed in the US with a market value of about $3.9B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -66%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87M | $381M | $22M | $285000 |
| Net income | -$145M | -$302M | $49M | -$198M | -$88M |
| Free cash flow | -$123M | -$168M | $11M | -$182M | -$75M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
| Net margin | — | -345.4% | 12.9% | -892.4% | -30853.0% |
| ROIC | -38.9% | -188.5% | 8.0% | -45.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $43.00, 42% above the current price; targets range from $25.00 to $57.00; the consensus rating is “Strong buy”; expected EPS is $-1.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Amylyx Pharmaceuticals pay a dividend?
Not currently.
Is Amylyx Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Amylyx Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.